Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
senaparib + temozolomide
- Development stage
- Unknown
- Lead developer
- IMPACT Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Senaparib + temozolomide is an investigational fixed-dose combination of **senaparib** (a novel oral PARP [poly(ADP-ribose) polymerase] inhibitor) and **temozolomide** (an orally available alkylating agent). Senaparib inhibits PARP enzymatic activity and traps PARP at sites of DNA damage, leading to impaired DNA repair in tumor cells. Temozolomide induces DNA damage via methylation. Their combination is designed to promote synthetic lethality: senaparib prevents repair of DNA damage caused by temozolomide, thereby enhancing cytotoxicity. The combination is intended to treat advanced solid tumors and small cell lung cancer (SCLC), with promising results for tolerability and antitumor activity in early clinical trials. The FDA has granted Orphan Drug Designation for this combination in SCLC. IMPACT Therapeutics developed senaparib, and is advancing this combination into global multi-center phase Ib/II trials[1][2][3][5][7].
- Brand names
- senaparib + temozolomide
- Other names
- senaparib (IMP4297) + temozolomideIMP4297 + TMZ
02
Targets
DNAPARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on senaparib + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on senaparib + temozolomide.